speb/financial-data huggingface dataset:
Financial ratios for ASTC — annual report dated 2024-06-30
Total revenue: 1664000
Gross profit: 751000
Operating income: -13280000
Net income: -11666000
Capital expenditures: 579000
Operating cash flow: -9725000
Depreciation & amortization: 874000
Net tangible assets: 34807000
Owner earnings: -11371000
Return on net tangible assets (%): -32.668716062860916
Buffett classification: The Gruesome
Stock price: 8.9
Shares outstanding: 2009050
Book value: 34807000
P/B ratio: 0.5137054328152384
Market cap (USD): 17880545
Debt to equity: 0.00861895595713506
Current ratio: 13.737341772151899
Quick ratio: 12.75870253164557
COGS to revenue (%): 54.86778846153846
R&D to revenue (%): 408.0528846153846
SG&A to revenue (%): 435.15625
Free cash flow (dilution-adjusted): -11782000
Buyback yield (%): 0
Retained earnings: -237020000
Inventory turnover: 0.3690379951495554
Receivables turnover: 21.61038961038961
Capitalized R&D asset: 11453700
ROCI (R&D-adjusted, %): -24.79077947931632
Rosenberg metric: 0.07959220175281703
FCF margin (%): -708.0528846153845
Revenue growth (%): 121.86666666666666
Rule of 40 score: -586.1862179487179
Financial ratios for ASTC — quarterly report dated 2024-09-30
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 7.99
Shares outstanding: 2009050
Market cap (USD): 16052309.5
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for ASTC — quarterly report dated 2024-12-31
Capital expenditures: 319000
Buffett classification: The Gruesome
Stock price: 6.72
Shares outstanding: 2009050
Market cap (USD): 13500816
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for ASTC — quarterly report dated 2025-03-31
Total revenue: 534000
Gross profit: 237000
Operating income: -3867000
Net income: -3633000
Capital expenditures: 27000
Operating cash flow: -3861000
Depreciation & amortization: 283000
Net tangible assets: 24702000
Owner earnings: -3377000
Return on net tangible assets (%): -13.670957817180796
Buffett classification: The Gruesome
Stock price: 6.48
Shares outstanding: 2009050
Book value: 24752000
P/B ratio: 0.525963316095669
Market cap (USD): 13018644
Debt to equity: 0.004888493859082094
Current ratio: 9.8615569823435
Quick ratio: 8.757223113964686
COGS to revenue (%): 55.61797752808989
R&D to revenue (%): 372.4719101123596
SG&A to revenue (%): 396.0674157303371
Free cash flow (dilution-adjusted): -4036000
Buyback yield (%): 0
Retained earnings: -247940000
Inventory turnover: 0.10792151162790697
Receivables turnover: 1.0210325047801148
Capitalized R&D asset: 1989000
ROCI (R&D-adjusted, %): -9.414946830190077
FCF margin (%): -755.8052434456929
Rule of 40 score: -755.8052434456929
Financial ratios for ASTC — quarterly report dated 2025-06-30
Total revenue: 220000
Gross profit: 74000
Operating income: -2918000
Net income: -2930000
Capital expenditures: 348000
Operating cash flow: -2361000
Depreciation & amortization: 331000
Net tangible assets: 22052000
Owner earnings: -2947000
Return on net tangible assets (%): -13.363867222927626
Buffett classification: The Gruesome
Stock price: 5.78
Shares outstanding: 2009050
Book value: 22100000
P/B ratio: 0.5254438461538462
Market cap (USD): 11612309
Debt to equity: 0.12122171945701357
Current ratio: 8.965728274173806
Quick ratio: 7.7707058343533255
COGS to revenue (%): 66.36363636363637
R&D to revenue (%): 803.1818181818181
SG&A to revenue (%): 556.8181818181819
Free cash flow (dilution-adjusted): -2910000
Buyback yield (%): 0
Retained earnings: -250870000
Inventory turnover: 0.049846363946739504
Receivables turnover: 0.4536082474226804
Capitalized R&D asset: 3099630
ROCI (R&D-adjusted, %): -8.694667379221736
Rosenberg metric: -0.08195072900955254
FCF margin (%): -1322.7272727272727
Revenue growth (%): -58.80149812734082
Rule of 40 score: -1381.5287708546136
Financial ratios for ASTC — annual report dated 2025-06-30
Total revenue: 1049000
Gross profit: 475000
Operating income: -14734000
Net income: -13850000
Capital expenditures: 833000
Operating cash flow: -12952000
Depreciation & amortization: 1156000
Net tangible assets: 22052000
Owner earnings: -13527000
Return on net tangible assets (%): -61.341374931978955
Buffett classification: The Gruesome
Stock price: 5.78
Shares outstanding: 2009050
Book value: 22100000
P/B ratio: 0.5254438461538462
Market cap (USD): 11612309
Debt to equity: 0.12122171945701357
Current ratio: 8.965728274173806
Quick ratio: 7.7707058343533255
COGS to revenue (%): 54.71877979027645
R&D to revenue (%): 776.1677788369876
SG&A to revenue (%): 673.6892278360343
Free cash flow (dilution-adjusted): -14665000
Buyback yield (%): 0
Retained earnings: -250870000
Inventory turnover: 0.19597132127005804
Receivables turnover: 2.162886597938144
Capitalized R&D asset: 14536330
ROCI (R&D-adjusted, %): -34.37806867065923
Rosenberg metric: -0.0406480117820324
FCF margin (%): -1397.998093422307
Revenue growth (%): -36.95913461538461
Rule of 40 score: -1434.9572280376915
Financial ratios for ASTC — quarterly report dated 2025-09-30
Total revenue: 297000
Gross profit: 188000
Operating income: -3536000
Net income: -3465000
Capital expenditures: 448000
Operating cash flow: -3936000
Depreciation & amortization: 302000
Net tangible assets: 19037000
Owner earnings: -3611000
Return on net tangible assets (%): -18.968324841098912
Buffett classification: The Gruesome
Stock price: 4.9
Shares outstanding: 2009050
Book value: 19087000
P/B ratio: 0.5157617750301252
Market cap (USD): 9844345
Debt to equity: 0.13328443443181223
Current ratio: 9.786444324905863
Quick ratio: 8.128563743948359
COGS to revenue (%): 36.7003367003367
R&D to revenue (%): 654.5454545454546
SG&A to revenue (%): 599.3265993265993
Free cash flow (dilution-adjusted): -4688000
Buyback yield (%): 0
Retained earnings: -254335000
Inventory turnover: 0.03536664503569111
Receivables turnover: 0.8389830508474576
Capitalized R&D asset: 3784260
ROCI (R&D-adjusted, %): -13.876272289656455
Rosenberg metric: 0.06451612903225806
FCF margin (%): -1578.4511784511783
Revenue growth (%): 35
Rule of 40 score: -1543.4511784511783
Financial ratios for ASTC — quarterly report dated 2025-12-31
Total revenue: 148000
Gross profit: 8000
Operating income: -3901000
Net income: -3927000
Capital expenditures: 411000
Operating cash flow: -3543000
Depreciation & amortization: 293000
Net tangible assets: 15468000
Owner earnings: -4045000
Return on net tangible assets (%): -26.150762865270234
Buffett classification: The Gruesome
Stock price: 3.46
Shares outstanding: 2009050
Book value: 15518000
P/B ratio: 0.44795160458822014
Market cap (USD): 6951313
Debt to equity: 0.15801005284186107
Current ratio: 7.559536354056902
Quick ratio: 5.625395152792413
COGS to revenue (%): 94.5945945945946
R&D to revenue (%): 1237.837837837838
SG&A to revenue (%): 1403.3783783783783
Free cash flow (dilution-adjusted): -4143000
Buyback yield (%): 0
Retained earnings: -258262000
Inventory turnover: 0.038136747480250616
Receivables turnover: 1.112781954887218
Capitalized R&D asset: 3717590
ROCI (R&D-adjusted, %): -18.20385435243313
Rosenberg metric: -0.09259259259259259
FCF margin (%): -2799.324324324324
Revenue growth (%): -50.16835016835017
Rule of 40 score: -2849.4926744926743
Financial ratios for ATOM — annual report dated 2021-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 20.12
Shares outstanding: 38716500
Market cap (USD): 778975980
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for ATOM — annual report dated 2022-12-31
Total revenue: 382000
Gross profit: 301000
Operating income: -17526000
Net income: -17441000
Capital expenditures: 39000
Operating cash flow: -12499000
Depreciation & amortization: 1506000
Net tangible assets: 20314000
Owner earnings: -15974000
Return on net tangible assets (%): -78.6354238456237
Buffett classification: The Gruesome
Stock price: 6.22
Shares outstanding: 38716500
Book value: 20314000
P/B ratio: 11.85471251353746
Market cap (USD): 240816630
Debt to equity: 0.2401299596337501
Current ratio: 7.428473177441541
Quick ratio: 7.428473177441541
Interest coverage ratio: -68.72941176470589
COGS to revenue (%): 21.20418848167539
R&D to revenue (%): 2627.748691099476
SG&A to revenue (%): 2039.0052356020942
Free cash flow (dilution-adjusted): -15905000
Buyback yield (%): 0
Retained earnings: -183295000
Capitalized R&D asset: 10038000
ROCI (R&D-adjusted, %): -31.99740098644378
FCF margin (%): -4163.612565445026
Rule of 40 score: -4163.612565445026
Financial ratios for ATOM — annual report dated 2023-12-31
Total revenue: 550000
Gross profit: 522000
Operating income: -20677000
Net income: -19790000
Capital expenditures: 16000
Operating cash flow: -14557000
Depreciation & amortization: 1439000
Net tangible assets: 18170000
Owner earnings: -18367000
Return on net tangible assets (%): -101.0842047330765
Buffett classification: The Gruesome
Stock price: 7.01
Shares outstanding: 38716500
Book value: 18170000
P/B ratio: 14.936855531095212
Market cap (USD): 271402665
Debt to equity: 0.20016510731975784
Current ratio: 5.34976402726796
Quick ratio: 5.34976402726796
Interest coverage ratio: -106.58247422680412
COGS to revenue (%): 5.090909090909091
R&D to revenue (%): 2277.2727272727275
SG&A to revenue (%): 1577.0909090909092
Free cash flow (dilution-adjusted): -18601000
Buyback yield (%): 0
Retained earnings: -203085000
Receivables turnover: 0.8744038155802861
Capitalized R&D asset: 19250460
ROCI (R&D-adjusted, %): -39.71320744772771
Rosenberg metric: 0.022016337915919507
FCF margin (%): -3382
Revenue growth (%): 43.97905759162304
Rule of 40 score: -3338.020942408377
Financial ratios for ATOM — quarterly report dated 2024-09-30
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 2.63
Shares outstanding: 38716500
Market cap (USD): 101824395
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for ATOM — quarterly report dated 2024-12-31
Capital expenditures: 8000
Buffett classification: The Gruesome
Stock price: 11.6
Shares outstanding: 38716500
Market cap (USD): 449111400
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for ATOM — annual report dated 2024-12-31
Total revenue: 135000
Gross profit: 12000
Operating income: -19336000
Net income: -18435000
Capital expenditures: 14000
Operating cash flow: -13236000
Depreciation & amortization: 1365000
Net tangible assets: 25077000
Owner earnings: -17084000
Return on net tangible assets (%): -68.12617139211228
Buffett classification: The Gruesome
Stock price: 11.6
Shares outstanding: 38716500
Book value: 25077000
P/B ratio: 17.909295370259603
Market cap (USD): 449111400
Debt to equity: 0.07911632172907446
Current ratio: 7.576062639821029
Quick ratio: 7.576062639821029
Interest coverage ratio: -149.89147286821705
COGS to revenue (%): 91.11111111111111
R&D to revenue (%): 8169.62962962963
SG&A to revenue (%): 6162.222222222222
Free cash flow (dilution-adjusted): -17117000
Buyback yield (%): 0
Retained earnings: -221520000
Receivables turnover: 1.7088607594936709
Capitalized R&D asset: 22733290
ROCI (R&D-adjusted, %): -40.39729123503812
Rosenberg metric: -0.0407185628742515
FCF margin (%): -12679.25925925926
Revenue growth (%): -75.45454545454545
Rule of 40 score: -12754.713804713805
Financial ratios for ATOM — quarterly report dated 2025-03-31
Total revenue: 4000
Gross profit: 4000
Operating income: -5463000
Net income: -5209000
Capital expenditures: 4000
Operating cash flow: -4782000
Depreciation & amortization: 324000
Net tangible assets: 23283000
Owner earnings: -4889000
Return on net tangible assets (%): -20.998153158957177
Buffett classification: The Gruesome
Stock price: 4
Shares outstanding: 38716500
Book value: 23283000
P/B ratio: 6.6514624404071645
Market cap (USD): 154866000
Debt to equity: 0.06919211441824508
Current ratio: 8.592086834733893
Quick ratio: 8.592086834733893
Interest coverage ratio: -260.14285714285717
COGS to revenue (%): 0
R&D to revenue (%): 81375
SG&A to revenue (%): 55300
Free cash flow (dilution-adjusted): -5795000
Buyback yield (%): 0
Retained earnings: -226729000
Receivables turnover: 0.04938271604938271
Capitalized R&D asset: 3255000
ROCI (R&D-adjusted, %): -12.356009155378784
FCF margin (%): -144875
Rule of 40 score: -144875
Financial ratios for ATOM — quarterly report dated 2025-06-30
Total revenue: 0
Gross profit: -62000
Operating income: -5255000
Net income: -4967000
Capital expenditures: 10000
Operating cash flow: -3505000
Depreciation & amortization: 326000
Net tangible assets: 21291000
Owner earnings: -4651000
Return on net tangible assets (%): -21.84491099525621
Buffett classification: The Gruesome
Stock price: 5.04
Shares outstanding: 38716500
Book value: 21291000
P/B ratio: 9.164959842186839
Market cap (USD): 195131160
Debt to equity: 0.059743553614203186
Current ratio: 8.144647332617257
Quick ratio: 8.144647332617257
Interest coverage ratio: -291.94444444444446
Free cash flow (dilution-adjusted): -4793000
Buyback yield (%): 0
Retained earnings: -231696000
Receivables turnover: 0
Capitalized R&D asset: 5184850
ROCI (R&D-adjusted, %): -16.38222505918916
Rosenberg metric: -0.020276497695852536
Revenue growth (%): -100
Rule of 40 score: -100
Financial ratios for ATOM — quarterly report dated 2025-09-30
Total revenue: 11000
Gross profit: -117000
Operating income: -5793000
Net income: -5573000
Capital expenditures: 13000
Operating cash flow: -3362000
Depreciation & amortization: 299000
Net tangible assets: 19030000
Owner earnings: -5287000
Return on net tangible assets (%): -27.782448765107727
Buffett classification: The Gruesome
Stock price: 4.42
Shares outstanding: 38716500
Book value: 19030000
P/B ratio: 8.992481870730424
Market cap (USD): 171126930
Debt to equity: 0.041723594324750396
Current ratio: 7.2277567846101
Quick ratio: 7.2277567846101
Interest coverage ratio: -482.75
COGS to revenue (%): 1163.6363636363637
R&D to revenue (%): 30036.363636363636
SG&A to revenue (%): 21563.636363636364
Free cash flow (dilution-adjusted): -4717000
Buyback yield (%): 0
Retained earnings: -237269000
Receivables turnover: 0.05472636815920398
Capitalized R&D asset: 6390830
ROCI (R&D-adjusted, %): -22.3307683764325
Rosenberg metric: -0.018308921438082555
FCF margin (%): -42881.818181818184
Rule of 40 score: -42881.818181818184
Financial ratios for ATOM — quarterly report dated 2025-12-31
Total revenue: 50000
Gross profit: -81000
Operating income: -4612000
Net income: -4425000
Capital expenditures: 22000
Operating cash flow: -3222000
Depreciation & amortization: 288000
Net tangible assets: 18381000
Owner earnings: -4159000
Return on net tangible assets (%): -22.626625319623525
Buffett classification: The Gruesome
Stock price: 2.21
Shares outstanding: 38716500
Book value: 18381000
P/B ratio: 4.654995103639628
Market cap (USD): 85563465
Debt to equity: 0.06958272128828681
Current ratio: 9.801
Quick ratio: 9.801
Interest coverage ratio: -512.4444444444445
COGS to revenue (%): 262
R&D to revenue (%): 5480
SG&A to revenue (%): 3582
Free cash flow (dilution-adjusted): -4578000
Buyback yield (%): 0
Retained earnings: -241694000
Receivables turnover: 0.9259259259259259
Capitalized R&D asset: 5945000
ROCI (R&D-adjusted, %): -19.52232606438214
Rosenberg metric: 0.010895883777239709
FCF margin (%): -9156
Revenue growth (%): 354.54545454545456
Rule of 40 score: -8801.454545454546
Financial ratios for ATOM — annual report dated 2025-12-31
Total revenue: 65000
Gross profit: -256000
Operating income: -21123000
Net income: -20174000
Capital expenditures: 49000
Operating cash flow: -14871000
Depreciation & amortization: 1237000
Net tangible assets: 18381000
Owner earnings: -18986000
Return on net tangible assets (%): -103.29144225014961
Buffett classification: The Gruesome
Stock price: 2.21
Shares outstanding: 38716500
Book value: 18381000
P/B ratio: 4.654995103639628
Market cap (USD): 85563465
Debt to equity: 0.06958272128828681
Current ratio: 9.801
Quick ratio: 9.801
Interest coverage ratio: -352.05
COGS to revenue (%): 493.84615384615387
R&D to revenue (%): 18927.69230769231
SG&A to revenue (%): 13175.384615384615
Free cash flow (dilution-adjusted): -19883000
Buyback yield (%): 0
Retained earnings: -241694000
Receivables turnover: 1.2037037037037037
Capitalized R&D asset: 23825680
ROCI (R&D-adjusted, %): -48.399282860827356
Rosenberg metric: -0.024299573850757095
FCF margin (%): -30589.230769230766
Revenue growth (%): -51.85185185185185
Rule of 40 score: -30641.082621082616
Financial ratios for BCT.TO — annual report dated 2021-07-31
Total revenue: 0
Operating income: -5622858.064516129
Net income: -11142096.774193548
Capital expenditures: 0
Operating cash flow: -6250151.612903226
Depreciation & amortization: 12303.225806451614
Net tangible assets: 22117831.451612905
Owner earnings: -11129793.548387095
Return on net tangible assets (%): -50.3204555687826
Buffett classification: The Gruesome
Stock price: 769.6854838709677
Shares outstanding: 8699787
Book value: 22315904.032258064
P/B ratio: 300.0595340878871
Market cap (USD): 6696099766.669354
Debt to equity: 0.0009390814543121478
Current ratio: 103.80508086459109
Quick ratio: 103.80508086459109
Interest coverage ratio: -88.75861191027828
Free cash flow (dilution-adjusted): -7837430.645161291
Buyback yield (%): 0
Retained earnings: -23501529.83870968
Receivables turnover: 0
Capitalized R&D asset: 1629757.2580645161
ROCI (R&D-adjusted, %): -9.45266294711358
Rule of 40 score: 0
Financial ratios for BCT.TO — annual report dated 2022-07-31
Total revenue: 0
Operating income: -11941838.28125
Net income: -20967892.96875
Capital expenditures: 0
Operating cash flow: -9753418.75
Depreciation & amortization: 11931.25
Net tangible assets: 7889525.78125
Owner earnings: -20955961.71875
Return on net tangible assets (%): -265.6175073101768
Buffett classification: The Gruesome
Stock price: 973.2734375
Shares outstanding: 8699787
Book value: 8069478.125
P/B ratio: 1049.296059527742
Market cap (USD): 8467271599.0078125
Debt to equity: 0
Current ratio: 44.997646338755075
Quick ratio: 44.997646338755075
Interest coverage ratio: -15613.435137895813
Free cash flow (dilution-adjusted): -12155437.5
Buyback yield (%): 0.09385154984199613
Retained earnings: -47148310.15625
Receivables turnover: 0
Capitalized R&D asset: 7358725.644153226
ROCI (R&D-adjusted, %): -20.827012403806975
Rule of 40 score: 0
Financial ratios for BCT.TO — annual report dated 2023-07-31
Total revenue: 0
Operating income: -17497942.857142854
Net income: -15264957.894736841
Capital expenditures: 0
Operating cash flow: -17853278.19548872
Depreciation & amortization: 11481.954887218044
Net tangible assets: -3001690.977443609
Owner earnings: -15253475.939849623
Buffett classification: The Gruesome
Stock price: 979.1578947368421
Shares outstanding: 8699787
Book value: -2839985.7142857164
Market cap (USD): 8518465123.578947
Debt to equity: 0
Current ratio: 14.95928406839575
Quick ratio: 14.95928406839575
Free cash flow (dilution-adjusted): -19502744.360902254
Buyback yield (%): 0.0004174390336800567
Retained earnings: -60640775.18796992
Receivables turnover: 0
Capitalized R&D asset: 16267874.810516082
ROCI (R&D-adjusted, %): -35.21107699806472
Rule of 40 score: 0
Financial ratios for BCT.TO — annual report dated 2024-07-31
Total revenue: 0
Operating income: -24152228.98550725
Net income: -3472076.811594203
Capital expenditures: 331015.2173913044
Operating cash flow: -17482701.449275363
Depreciation & amortization: 60794.92753623189
Net tangible assets: -1871163.7681159421
Owner earnings: -3742297.1014492754
Buffett classification: The Gruesome
Stock price: 111.95652173913044
Shares outstanding: 8699787
Book value: -1945602.8985507255
Market cap (USD): 973997892.3913044
Debt to equity: 0
Current ratio: 0.48971680933667533
Quick ratio: 0.48971680933667533
Free cash flow (dilution-adjusted): -19121019.565217394
Buyback yield (%): 0
Retained earnings: -61915722.46376812
Receivables turnover: 0
Capitalized R&D asset: 29488078.71012535
ROCI (R&D-adjusted, %): -59.83600455308973
Rule of 40 score: 0
Financial ratios for BCT.TO — quarterly report dated 2024-10-31
Total revenue: 0
Operating income: -3707073.3812949643
Net income: -4174226.618705036
Capital expenditures: 0
Operating cash flow: -5003651.798561151
Depreciation & amortization: 19177.697841726622
Net tangible assets: 2767381.294964029
Owner earnings: -4155048.9208633094
Return on net tangible assets (%): -150.14370908788402
Buffett classification: The Gruesome
Stock price: 125.17985611510792
Shares outstanding: 8699787
Book value: 2671233.8129496407
P/B ratio: 407.69103760690433
Market cap (USD): 1089038084.8920865
Debt to equity: 0
Current ratio: 1.6475635825103296
Quick ratio: 1.6475635825103296
Free cash flow (dilution-adjusted): -5195717.26618705
Buyback yield (%): 0
Retained earnings: -65644512.23021583
Receivables turnover: 0
Capitalized R&D asset: 2636935.971223022
ROCI (R&D-adjusted, %): -29.801571914895643
Rule of 40 score: 0
Financial ratios for BCT.TO — quarterly report dated 2025-01-31
Total revenue: 0
Operating income: -4944443.448275862
Net income: -4338910.344827587
Capital expenditures: 0
Operating cash flow: -4082911.724137931
Depreciation & amortization: 18384.137931034482
Net tangible assets: 2352249.6551724137
Owner earnings: -4320526.206896552
Return on net tangible assets (%): -183.6763456377197
Buffett classification: The Gruesome
Stock price: 49.86206896551724
Shares outstanding: 8699787
Book value: 2225442.068965517
P/B ratio: 194.92279103942465
Market cap (USD): 433789379.3793103
Debt to equity: 0
Current ratio: 1.3692974242368048
Quick ratio: 1.3692974242368048
Free cash flow (dilution-adjusted): -4279527.586206896
Buyback yield (%): 0
Retained earnings: -67267097.93103449
Receivables turnover: 0
Capitalized R&D asset: 5687282.96278839
ROCI (R&D-adjusted, %): -37.595944388439726
Rule of 40 score: 0
Financial ratios for BCT.TO — quarterly report dated 2025-04-30
Total revenue: 0
Operating income: -4585692.028985508
Net income: -4439784.057971015
Capital expenditures: 0
Operating cash flow: -5190418.115942029
Depreciation & amortization: 19315.942028985508
Net tangible assets: 8860049.27536232
Owner earnings: -4420468.115942029
Return on net tangible assets (%): -49.89213918069615
Buffett classification: The Gruesome
Stock price: 44.34782608695653
Shares outstanding: 8699787
Book value: 8653009.420289855
P/B ratio: 44.58756741497241
Market cap (USD): 385816640.8695653
Debt to equity: 0
Current ratio: 3.414096276456583
Quick ratio: 3.414096276456583
Interest coverage ratio: -171.13104735119936
Free cash flow (dilution-adjusted): -5353327.536231885
Buyback yield (%): 0
Retained earnings: -75118981.1594203
Receivables turnover: 0
Capitalized R&D asset: 6982597.173452124
ROCI (R&D-adjusted, %): -27.515370443083636
Rule of 40 score: 0
Financial ratios for BCT.TO — quarterly report dated 2025-10-31
Total revenue: 0
Operating income: -5944959.285714286
Net income: -5855403.571428572
Capital expenditures: 0
Operating cash flow: -5503425.714285715
Depreciation & amortization: 19040.714285714286
Net tangible assets: 6998039.285714286
Owner earnings: -5836362.857142857
Return on net tangible assets (%): -83.39997274746854
Buffett classification: The Gruesome
Stock price: 10.950000000000001
Shares outstanding: 8699787
Book value: 6678860
P/B ratio: 14.263312548848159
Market cap (USD): 95262667.65
Debt to equity: 0
Current ratio: 3.4204892860361453
Quick ratio: 3.4204892860361453
Free cash flow (dilution-adjusted): -5713915.714285715
Buyback yield (%): 0
Retained earnings: -85680806.42857143
Receivables turnover: 0
Capitalized R&D asset: 8403192.563261228
ROCI (R&D-adjusted, %): -34.02791079554907
Rule of 40 score: 0
Financial ratios for BCT.TO — quarterly report dated 2026-01-31
Total revenue: 0
Operating income: -5578715.555555555
Net income: -5349496.296296296
Capital expenditures: 0
Operating cash flow: -5901702.222222222
Depreciation & amortization: 19745.925925925923
Net tangible assets: 22770037.037037037
Owner earnings: -5329750.370370369
Return on net tangible assets (%): -23.40685859096831
Buffett classification: The Gruesome
Stock price: 4.355555555555555
Shares outstanding: 8699787
Book value: 22380598.518518515
P/B ratio: 1.693091700324567
Market cap (USD): 37892405.599999994
Debt to equity: 0
Current ratio: 10.101515907771029
Quick ratio: 10.101515907771029
Free cash flow (dilution-adjusted): -6113447.407407407
Buyback yield (%): 0
Retained earnings: -94203665.92592593
Receivables turnover: 0
Capitalized R&D asset: 8833078.913515069
ROCI (R&D-adjusted, %): -17.03690697835579
Rule of 40 score: 0
Financial ratios for BHS.V — annual report dated 2021-12-31
Gross profit: -221144.88188976378
Capital expenditures: 534619.6850393701
Buffett classification: The Gruesome
Stock price: 0.07874015748031496
Shares outstanding: 417654900
Market cap (USD): 32886212.598425195
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for BHS.V — annual report dated 2022-12-31
Total revenue: 0
Gross profit: -205104.41176470587
Operating income: -1567073.5294117646
Net income: -2224219.117647059
Capital expenditures: 52355.147058823524
Operating cash flow: -1413580.1470588234
Depreciation & amortization: 205104.41176470587
Net tangible assets: 929838.9705882352
Owner earnings: -2071469.8529411766
Return on net tangible assets (%): -222.77726772741332
Buffett classification: The Gruesome
Stock price: 0.029411764705882353
Shares outstanding: 417654900
Book value: 929838.9705882352
P/B ratio: 13.210854820687643
Market cap (USD): 12283967.647058824
Debt to equity: 0.35879394044351454
Current ratio: 0.6441312768347915
Quick ratio: 0.6441312768347915
Free cash flow (dilution-adjusted): -1465935.294117647
Buyback yield (%): 0
Retained earnings: -29003095.588235293
Receivables turnover: 0
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -168.53171129409662
Rule of 40 score: 0
Financial ratios for BHS.V — annual report dated 2023-12-31
Total revenue: 0
Gross profit: -207076.51515151514
Operating income: -983452.2727272727
Net income: -1534123.4848484849
Capital expenditures: 0
Operating cash flow: -479706.0606060606
Depreciation & amortization: 207076.51515151514
Net tangible assets: 375099.24242424243
Owner earnings: -1327046.9696969697
Return on net tangible assets (%): -353.78556382048384
Buffett classification: The Gruesome
Stock price: 0.05303030303030303
Shares outstanding: 417654900
Book value: 375099.24242424243
P/B ratio: 59.04668259511119
Market cap (USD): 22148365.90909091
Debt to equity: 0.8948561087873713
Current ratio: 0.7308337457878786
Quick ratio: 0.7308337457878786
Interest coverage ratio: -3.2291739737170064
Free cash flow (dilution-adjusted): -508746.9696969697
Buyback yield (%): 0
Retained earnings: -31416100.757575758
Receivables turnover: 0
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -124.64457069555357
Rule of 40 score: 0
Financial ratios for BHS.V — quarterly report dated 2024-09-30
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 0.037037037037037035
Shares outstanding: 417654900
Market cap (USD): 15468700
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for BHS.V — annual report dated 2024-12-31
Total revenue: 0
Operating income: -2222377.6223776224
Net income: -2789006.2937062937
Capital expenditures: 15812.587412587412
Operating cash flow: -874220.979020979
Depreciation & amortization: 192079.7202797203
Net tangible assets: -328199.3006993007
Owner earnings: -2612739.160839161
Buffett classification: The Gruesome
Stock price: 0.06293706293706294
Shares outstanding: 417654900
Book value: -328199.30069930083
Market cap (USD): 26285972.72727273
Debt to equity: -0.9350982794438819
Current ratio: 0.5527105925972815
Quick ratio: 0.5527105925972815
Interest coverage ratio: -2.6189314627778804
Free cash flow (dilution-adjusted): -1147102.7972027974
Buyback yield (%): 0
Retained earnings: -31788483.916083917
Receivables turnover: 0
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -4125.6117666913315
Rule of 40 score: 0
Financial ratios for BHS.V — quarterly report dated 2024-12-31
Total revenue: 0
Operating income: -654223.076923077
Net income: -675618.8811188812
Capital expenditures: 0
Operating cash flow: -347255.24475524476
Depreciation & amortization: 49205.594405594406
Net tangible assets: -328199.3006993007
Owner earnings: -626413.2867132868
Buffett classification: The Gruesome
Stock price: 0.06293706293706294
Shares outstanding: 417654900
Book value: -328199.30069930083
Market cap (USD): 26285972.72727273
Debt to equity: -0.9350982794438819
Current ratio: 0.5527105925972815
Quick ratio: 0.5527105925972815
Interest coverage ratio: -7.897843062766452
Free cash flow (dilution-adjusted): -402381.8181818182
Buyback yield (%): 0
Retained earnings: -31788483.916083917
Receivables turnover: 0
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -1214.4967610442548
Rule of 40 score: 0
Financial ratios for BHS.V — quarterly report dated 2025-03-31
Total revenue: 0
Operating income: -484095.10489510495
Net income: -738893.7062937063
Capital expenditures: 0
Operating cash flow: -449127.97202797205
Depreciation & amortization: 47839.86013986014
Net tangible assets: -585849.6503496504
Owner earnings: -691053.8461538461
Buffett classification: The Gruesome
Stock price: 0.027972027972027975
Shares outstanding: 417654900
Book value: -585849.6503496503
Market cap (USD): 11682654.545454547
Debt to equity: -0.5233782743370755
Current ratio: 0.4041907307970987
Quick ratio: 0.4041907307970987
Interest coverage ratio: -1.394153968848557
Free cash flow (dilution-adjusted): -449127.97202797205
Buyback yield (%): 0
Retained earnings: -32527377.622377623
Receivables turnover: 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for BHS.V — quarterly report dated 2025-06-30
Total revenue: 0
Operating income: -248725.54744525545
Net income: -107289.0510948905
Capital expenditures: 0
Operating cash flow: -217611.67883211677
Depreciation & amortization: 49933.57664233576
Net tangible assets: -488846.71532846714
Owner earnings: -57355.474452554736
Buffett classification: The Gruesome
Stock price: 0.029197080291970802
Shares outstanding: 417654900
Book value: -488846.7153284671
Market cap (USD): 12194303.649635036
Debt to equity: -0.6111359971331304
Current ratio: 0.4540744442443853
Quick ratio: 0.4540744442443853
Interest coverage ratio: -18.25728675525075
Free cash flow (dilution-adjusted): -217611.67883211677
Buyback yield (%): 0
Retained earnings: -34059223.35766423
Receivables turnover: 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for BHS.V — quarterly report dated 2025-09-30
Total revenue: 0
Operating income: -361485.6115107914
Net income: -333040.2877697842
Capital expenditures: 0
Operating cash flow: -398920.86330935254
Depreciation & amortization: 49211.51079136691
Net tangible assets: -62477.69784172662
Owner earnings: -283828.7769784173
Buffett classification: The Gruesome
Stock price: 0.03597122302158274
Shares outstanding: 417654900
Book value: -62477.69784172671
Market cap (USD): 15023557.553956836
Debt to equity: -4.568525171572008
Current ratio: 0.7381847248368869
Quick ratio: 0.7381847248368869
Interest coverage ratio: -37.074079539585334
Free cash flow (dilution-adjusted): -464992.80575539573
Buyback yield (%): 0
Retained earnings: -33902202.87769785
Receivables turnover: 0
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -109.34752520064765
Rule of 40 score: 0
Financial ratios for BIOX — annual report dated 2021-06-30
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 14.05
Shares outstanding: 63815891
Market cap (USD): 896613268.5500001
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for BIOX — annual report dated 2022-06-30
Total revenue: 2627014.220587059
Gross profit: 997960.6174518116
Operating income: 353671.99872030714
Net income: -31263.728705110774
Capital expenditures: 11293.441574022234
Operating cash flow: -140089.37055106775
Depreciation & amortization: 73485.84339758458
Net tangible assets: 118658.8178837079
Owner earnings: 30928.67311845158
Capex to operating income (%): 3.1931964121800256
Buffett classification: The Great
Stock price: 13.71
Shares outstanding: 63815891
Book value: 1266086.9231384466
P/B ratio: 691.0393351518156
Market cap (USD): 874915865.61
Debt to equity: 1.0725851397225583
Current ratio: 1.3370045609887955
Quick ratio: 0.7706784247628706
Effective tax rate (%): 127.79441723082874
Interest coverage ratio: 2.95724199641677
COGS to revenue (%): 62.01160200690512
R&D to revenue (%): 2.1151900755605353
SG&A to revenue (%): 17.46324742083548
Free cash flow (dilution-adjusted): -223495.41709989603
Buyback yield (%): 0
Retained earnings: -261400.4079021035
Inventory turnover: 1.615212166300883
Receivables turnover: 2.56447395550663
Capitalized R&D asset: 55566.34407742142
ROCI (R&D-adjusted, %): 16.149063099465945
FCF margin (%): -8.507583070865582
Rule of 40 score: -8.507583070865582
Financial ratios for BIOX — annual report dated 2023-06-30
Total revenue: 1637311.4177531423
Gross profit: 698148.7899133422
Operating income: 207775.1190569131
Net income: 78751.65508626746
Capital expenditures: 43809.477710984465
Operating cash flow: 10105.36341634788
Depreciation & amortization: 75691.31470060114
Net tangible assets: 50365.34077601686
Owner earnings: 110633.49207588413
Return on net tangible assets (%): 219.66195477141684
Capex to operating income (%): 21.085045172797763
Buffett classification: The Great
Stock price: 13.36
P/E ratio: 10826.189022009152
Shares outstanding: 63815891
Book value: 1290093.32110235
P/B ratio: 660.867155743038
Market cap (USD): 852580303.76
Debt to equity: 0.7788683998023613
Current ratio: 1.329419946603245
Quick ratio: 0.8588209559361845
Effective tax rate (%): -5.593295113819796
Interest coverage ratio: 2.5072291266078914
COGS to revenue (%): 57.36004877609653
R&D to revenue (%): 3.65846829849949
SG&A to revenue (%): 20.39369179148044
Free cash flow (dilution-adjusted): -91301.05784994925
Buyback yield (%): 0.0013721403825525478
Retained earnings: -54270.50121008666
Inventory turnover: 1.7115184543932531
Receivables turnover: 2.2633686726362945
Capitalized R&D asset: 97129.96969808362
ROCI (R&D-adjusted, %): 10.788290168607958
Rosenberg metric: -5.395565112592922
FCF margin (%): -5.57627931131393
Revenue growth (%): -37.674055780815216
Rule of 40 score: -43.25033509212915
Financial ratios for BIOX — annual report dated 2024-06-30
Total revenue: 510245.4999506032
Gross profit: 200255.49347413253
Operating income: 48359.9139397798
Net income: 8001.166862424396
Capital expenditures: 10376.456382616714
Operating cash flow: 45792.583892249095
Depreciation & amortization: 23376.01071361925
Net tangible assets: 28804.467667043547
Owner earnings: 21000.72119342693
Return on net tangible assets (%): 72.9078608088799
Capex to operating income (%): 21.45673045559593
Buffett classification: The Great
Stock price: 11.21
P/E ratio: 89408.97626689883
Shares outstanding: 63815891
Book value: 385713.18236204574
P/B ratio: 1854.684181985047
Market cap (USD): 715376138.11
Debt to equity: 0.771088980682419
Current ratio: 1.2409861835124838
Quick ratio: 0.8576870159021874
Effective tax rate (%): 34.14123823434859
Interest coverage ratio: 1.826149183786462
COGS to revenue (%): 60.753109337854184
R&D to revenue (%): 3.6966406374851144
SG&A to revenue (%): 20.279858112329194
Free cash flow (dilution-adjusted): 5268.213701577404
Buyback yield (%): 0.00011268795879716588
Retained earnings: -10567.985378544221
Inventory turnover: 2.2372767084953535
Receivables turnover: 2.1516526839279035
Capitalized R&D asset: 77332.1838890237
ROCI (R&D-adjusted, %): 3.44418414587079
Rosenberg metric: -8.312003023841267
FCF margin (%): 1.0324860683901023
Revenue growth (%): -68.83638051881387
Rule of 40 score: -67.80389445042377
Financial ratios for BIOX — quarterly report dated 2024-09-30
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 7.87
Shares outstanding: 63815891
Market cap (USD): 502231062.17
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for BIOX — quarterly report dated 2024-12-31
Capital expenditures: 1647.6895769074085
Operating cash flow: -5196.20943180275
Depreciation & amortization: 1829.8609090380025
Buffett classification: The Gruesome
Stock price: 6.08
Shares outstanding: 63815891
Market cap (USD): 388000617.28000003
Free cash flow (dilution-adjusted): -9827.346796252108
Buyback yield (%): 0.0002317126566828035
Retained earnings: -15376.68625967526
Capitalized R&D asset: 1909.442472210906
Rule of 40 score: 0
Financial ratios for BIOX — quarterly report dated 2025-03-31
Total revenue: 46996.360361712505
Gross profit: 16978.72500093805
Operating income: 5065.475967130689
Net income: 2438.9328730629245
Capital expenditures: 2251.650031893738
Operating cash flow: 21892.245131514766
Depreciation & amortization: 10072.250572211175
Net tangible assets: 13813.466661663728
Owner earnings: 10259.53341338036
Return on net tangible assets (%): 74.27196709319512
Capex to operating income (%): 44.45090740740741
Buffett classification: The Good
Stock price: 4.57
P/E ratio: 29894.080428682195
Shares outstanding: 63815891
Book value: 323605.65457206115
P/B ratio: 901.2160873877973
Market cap (USD): 291638621.87
Debt to equity: 0.7922392393649269
Current ratio: 1.0177499792979108
Quick ratio: 0.7366052548525417
Interest coverage ratio: 1.0188679245283019
COGS to revenue (%): 63.87225548902197
R&D to revenue (%): 7.304884231536926
SG&A to revenue (%): 41.94306786427146
Free cash flow (dilution-adjusted): 15273.323702675323
Buyback yield (%): 0
Retained earnings: -16094.123109827024
Inventory turnover: 0.3425132192174192
Receivables turnover: 0.2518390825473068
Capitalized R&D asset: 4712.356173840315
ROCI (R&D-adjusted, %): 1.5206809019347864
FCF margin (%): 32.4989500998004
Rule of 40 score: 32.4989500998004
Financial ratios for BIOX — annual report dated 2025-06-30
Total revenue: 280774.56516428996
Gross profit: 107942.76930333633
Operating income: -641.7492819419995
Net income: -46676.763558872335
Capital expenditures: 4423.558198495658
Operating cash flow: 42035.33519200155
Depreciation & amortization: 18684.031737742476
Net tangible assets: -25713.490225145928
Owner earnings: -32416.290019625518
Buffett classification: The Gruesome
Stock price: 4.47
Shares outstanding: 63815891
Book value: 248661.64264717035
P/B ratio: 1147.1694216013661
Market cap (USD): 285257032.77
Debt to equity: 0.9369620125715535
Current ratio: 0.9122020540905824
Quick ratio: 0.6459494379427956
Interest coverage ratio: -0.029727172010330913
COGS to revenue (%): 61.55536052912214
R&D to revenue (%): 4.474303596782744
SG&A to revenue (%): 26.502699147232555
Free cash flow (dilution-adjusted): 26036.63148673804
Buyback yield (%): 0.00027369142514258277
Retained earnings: -54785.831725950324
Inventory turnover: 2.2801632774453875
Receivables turnover: 1.8753258047071981
Capitalized R&D asset: 44967.37926926241
ROCI (R&D-adjusted, %): -4.590043715415362
Rosenberg metric: -4.894126050933221
FCF margin (%): 9.27314462102477
Revenue growth (%): -44.972652342554376
Rule of 40 score: -35.699507721529606
Financial ratios for BIOX — quarterly report dated 2025-06-30
Total revenue: 62639.71429293397
Gross profit: 19665.191243482728
Operating income: -5825.502219452002
Net income: -40334.56364815579
Capital expenditures: 177.8012684989429
Operating cash flow: 22546.570588681214
Depreciation & amortization: 4134.555225188043
Net tangible assets: -25713.490225145928
Owner earnings: -36377.80969146669
Buffett classification: The Gruesome
Stock price: 4.47
Shares outstanding: 63815891
Book value: 248661.64264717035
P/B ratio: 1147.1694216013661
Market cap (USD): 285257032.77
Debt to equity: 0.9369620125715535
Current ratio: 0.9122020540905824
Quick ratio: 0.6459494379427956
Interest coverage ratio: -0.970110946391784
COGS to revenue (%): 68.605873341761
R&D to revenue (%): 3.564663542050514
SG&A to revenue (%): 30.467446721662196
Free cash flow (dilution-adjusted): 19839.040455514096
Buyback yield (%): 0
Retained earnings: -54785.831725950324
Inventory turnover: 0.5669612401755229
Receivables turnover: 0.41837789881106247
Capitalized R&D asset: 5163.140984771956
ROCI (R&D-adjusted, %): -1.6821070044018733
Rosenberg metric: 0.7825350968802836
FCF margin (%): 31.67166498036219
Revenue growth (%): 33.28630943081702
Rule of 40 score: 64.95797441117921
Financial ratios for BIOX — quarterly report dated 2025-09-30
Total revenue: 57021.66773440549
Gross profit: 26247.521741371565
Operating income: 5715.336411366632
Net income: -5396.046420865826
Capital expenditures: 494.9263996583236
Operating cash flow: 10586.80495725363
Depreciation & amortization: 4294.298274681335
Net tangible assets: -25607.826893763668
Owner earnings: -1596.6745458428145
Capex to operating income (%): 8.659619732515072
Buffett classification: The Great
Stock price: 1.41
Shares outstanding: 63815891
Book value: 212317.23625010118
P/B ratio: 423.8017030515916
Market cap (USD): 89980406.30999999
Debt to equity: 0.8963817054362186
Current ratio: 0.9447315801250484
Quick ratio: 0.6450999940396723
Interest coverage ratio: 0.9077810027471499
COGS to revenue (%): 53.96921418779471
R&D to revenue (%): 7.382184473770886
SG&A to revenue (%): 21.365438643876146
Free cash flow (dilution-adjusted): 9577.122407051495
Buyback yield (%): 0
Retained earnings: -53292.14659685864
Inventory turnover: 0.465364031263606
Receivables turnover: 0.4536155382651379
Capitalized R&D asset: 6838.384197960009
ROCI (R&D-adjusted, %): 2.026701915520489
Rosenberg metric: 2.94789066489444
FCF margin (%): 16.795584534040014
Revenue growth (%): -8.968825324227598
Rule of 40 score: 7.8267592098124155
Financial ratios for BIOX — quarterly report dated 2025-12-31
Total revenue: 50757.85985435656
Gross profit: 18128.015349744055
Operating income: 5390.699901480548
Net income: -125711.87607217411
Capital expenditures: 26.853095784331963
Operating cash flow: 11980.034998518764
Depreciation & amortization: 966.9925387016101
Net tangible assets: -34166.98840501829
Owner earnings: -124771.73662925683
Capex to operating income (%): 0.49813746406021975
Buffett classification: The Great
Stock price: 1.31
Shares outstanding: 63815891
Book value: 73453.00415435171
P/B ratio: 1138.1265909060467
Market cap (USD): 83598817.21000001
Debt to equity: 2.2459648267106926
Current ratio: 0.8954567790891735
Quick ratio: 0.6911183964654184
Interest coverage ratio: 1.114454954398706
COGS to revenue (%): 64.28530398688957
R&D to revenue (%): 3.186401226388616
SG&A to revenue (%): 17.14080793678944
Free cash flow (dilution-adjusted): 11831.515890567624
Buyback yield (%): 0
Retained earnings: -175964.7596607624
Inventory turnover: 0.7052821661447028
Receivables turnover: 0.44424553345401135
Capitalized R&D asset: 5174.5323885655425
ROCI (R&D-adjusted, %): 2.6219324703532028
Rosenberg metric: -1.9288782644972515
FCF margin (%): 23.309721734755374
Revenue growth (%): -10.984960855975634
Rule of 40 score: 12.32476087877974
Financial ratios for BM.V — annual report dated 2022-04-30
Total revenue: 0
Gross profit: -342.96875
Operating income: -147525
Net income: -208438.28125
Capital expenditures: 0
Operating cash flow: -25743.75
Depreciation & amortization: 342.96875
Net tangible assets: -57882.8125
Owner earnings: -208095.3125
Buffett classification: The Gruesome
Stock price: 0.1875
Shares outstanding: 34638067
Book value: -57882.8125
Market cap (USD): 6494637.5625
Debt to equity: -0.8584154406802538
Current ratio: 0.8466245971619957
Quick ratio: 0.8466245971619957
Interest coverage ratio: -2.4198992733843374
Free cash flow (dilution-adjusted): -25743.75
Buyback yield (%): 0
Retained earnings: -31485821.875
Receivables turnover: 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for BM.V — annual report dated 2023-04-30
Total revenue: 0
Gross profit: -1183.8235294117646
Operating income: -180279.41176470587
Net income: -173217.64705882352
Capital expenditures: 0
Operating cash flow: -144808.0882352941
Depreciation & amortization: 1183.8235294117646
Net tangible assets: 507598.52941176464
Owner earnings: -172033.82352941175
Return on net tangible assets (%): -33.891710389463654
Buffett classification: The Gruesome
Stock price: 0.10294117647058824
Shares outstanding: 34638067
Book value: 507598.5294117647
P/B ratio: 7.024613274154251
Market cap (USD): 3565683.3676470593
Debt to equity: 0
Current ratio: 7.182025516971555
Quick ratio: 7.182025516971555
Free cash flow (dilution-adjusted): -144808.0882352941
Buyback yield (%): 0
Retained earnings: -29806932.352941174
Receivables turnover: 0
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -35.516141461958995
Rule of 40 score: 0
Financial ratios for BM.V — annual report dated 2024-04-30
Total revenue: 0
Gross profit: 0
Operating income: -39047.44525547445
Net income: -17162.043795620437
Capital expenditures: 0
Operating cash flow: -22654.014598540143
Depreciation & amortization: 0
Net tangible assets: 486731.38686131383
Owner earnings: -17162.043795620437
Return on net tangible assets (%): -3.5259784470218443
Buffett classification: The Gruesome
Stock price: 0.0656934306569343
Shares outstanding: 34638067
Book value: 486731.3868613138
P/B ratio: 4.675049758406291
Market cap (USD): 2275493.452554744
Debt to equity: 0
Current ratio: 7.939675870348139
Quick ratio: 7.939675870348139
Free cash flow (dilution-adjusted): -22654.014598540143
Buyback yield (%): 0
Retained earnings: -29606525.547445253
Receivables turnover: 0
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -8.022380785277031
Rule of 40 score: 0
Financial ratios for BM.V — quarterly report dated 2024-10-31
Total revenue: 0
Operating income: -2255.395683453238
Net income: 3866.1870503597124
Capital expenditures: 0
Operating cash flow: -16558.992805755395
Net tangible assets: 487537.4100719425
Owner earnings: 3866.1870503597124
Return on net tangible assets (%): 0.7930031563709555
Buffett classification: The Gruesome
Stock price: 0.06474820143884892
P/E ratio: 145.0235406587272
Shares outstanding: 34638067
Book value: 487537.4100719425
P/B ratio: 4.6001650196184904
Market cap (USD): 2242752.5395683455
Debt to equity: 0
Current ratio: 11.176982359444347
Quick ratio: 11.176982359444347
Free cash flow (dilution-adjusted): -16558.992805755395
Buyback yield (%): 0
Retained earnings: -29172723.021582738
Receivables turnover: 0
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -0.4626097683704774
Rule of 40 score: 0
Financial ratios for BM.V — quarterly report dated 2025-01-31
Total revenue: 0
Operating income: -1300.6896551724137
Net income: 4282.068965517242
Capital expenditures: 0
Operating cash flow: -1649.6551724137933
Net tangible assets: 471645.5172413793
Owner earnings: 4282.068965517242
Return on net tangible assets (%): 0.9078998546541382
Buffett classification: The Gruesome
Stock price: 0.07586206896551724
P/E ratio: 153.41388991786113
Shares outstanding: 34638067
Book value: 471645.5172413793
P/B ratio: 5.571377934334085
Market cap (USD): 2627715.4275862067
Debt to equity: 0
Current ratio: 11.543199526580532
Quick ratio: 11.543199526580532
Free cash flow (dilution-adjusted): -1649.6551724137933
Buyback yield (%): 0
Retained earnings: -27961293.79310345
Receivables turnover: 0
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -0.27577655372890547
Rule of 40 score: 0
Financial ratios for BM.V — quarterly report dated 2025-04-30
Total revenue: 0
Operating income: -22936.231884057972
Net income: -18868.115942028988
Capital expenditures: 0
Operating cash flow: 16010.869565217392
Net tangible assets: 476701.44927536236
Owner earnings: -18868.115942028988
Return on net tangible assets (%): -3.9580571803820943
Buffett classification: The Gruesome
Stock price: 0.05072463768115943
Shares outstanding: 34638067
Book value: 476701.44927536236
P/B ratio: 3.685752164633776
Market cap (USD): 1757003.398550725
Debt to equity: 0
Current ratio: 8.323902926718958
Quick ratio: 8.323902926718958
Free cash flow (dilution-adjusted): 16010.869565217392
Buyback yield (%): 0
Retained earnings: -29398488.405797105
Receivables turnover: 0
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -4.811445805109995
Rule of 40 score: 0